Genprex, Inc. (GNPX), a clinical-stage gene therapy company focused on cancer and diabetes, announced Wednesday the expansion of multiple clinical trial sites for its Acclaim-3 clinical study of Reqorsa Therapy in combination with Genentech's Tecentriq to treat extensive-stage small cell lung cancer or ES-SCLC.
In pre-market activity on the Nasdaq, Genprex shares were gaining around 7.7 percent to trade at $3.06.
Through its collaboration agreement with a large network of integrated, community-based oncology practices, the company said it has added multiple clinical trial sites for the trial.
ES-SCLC is an aggressive form of lung cancer that is presently incurable. ES-SCLC has a median progression free survival or PFS of 5.4 months from the start of initial therapy. However, once patients start receiving maintenance therapy with Tecentriq they have a median PFS of only 2.6 months.
It is expected that the combination of REQORSA and Tecentriq as maintenance therapy may provide a new therapeutic option for the treatment of small cell lung cancer.
Genprex has received U.S. Food and Drug Administration Ophran Drug and Fast Track designations for the Acclaim-3 patient population.
For More Such Health News, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Health News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.